Mutations for which targeted therapies are approved in the first-line setting treatment of advanced/metastatic NSCLC include EGFR, EGFR ex20ins, MET14skip, BRAF V600E, ALK, ROS1, RET, and NTRK [17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.